Back to search results

Study of TIL Therapy and Combination Therapy for Ovarian Cancer

This study is for women aged 18 to 80 with recurrent ovarian cancer. It explores a treatment that uses your own immune cells, called tumor-infiltrating lymphocytes (TIL). First, a piece of your tumor will be removed to grow and prepare these special TIL cells. Then, you will receive chemotherapy (Fludarabine and Cyclophosphamide) to prepare your body for the TIL infusion. After the TIL infusion, you will receive high-dose IL-2 to help the cells grow. Once you recover, you will start a combination of oral cyclophosphamide, bevacizumab, and pembrolizumab. The study aims to see how safe this treatment is and if the TIL cells can be successfully made. There are 20 participants planned for this study, and its current status is unclear.

Study design
This is an interventional study with 20 planned participants. It is a single-arm study, meaning all participants receive the same treatment.
What's involved
You will undergo tumor resection, receive chemotherapy, TIL infusion, and high-dose IL-2. Afterward, you will take oral cyclophosphamide, bevacizumab, and pembrolizumab.
Compensation
Not stated in the trial record.
Follow-up
The study measures dose-limiting toxicity and manufacturing success at 12 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07720180

Study of Autologous, Metabolically Optimized, CD137+ Tumor-Infiltrating Lymphocytes Followed by Consolidative Oral Cyclophosphamide, Bevacizumab, and Pembrolizumab

Not Yet Recruiting
PHASE2Ages 18–80InterventionalTreatment
Medical University of South Carolina
~20 participants
Updated 2026-07-22 on ClinicalTrials.gov
What's tested:FludarabineCyclophosphamide

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Dose-limiting toxicity (DLT) incidence
Measured over 12 months
+1 more outcome measured

Conditions

Ovarian Cancer

Explore related trials

Malignant Ovarian NeoplasmX-linked Lymphoproliferative Syndrome 1

Where it's being run

1 sites across 1 states
South Carolina1

Study leadership

  • Brian Orr, MD · PRINCIPAL_INVESTIGATOR · Medical University of South Carolina

Who to contact

HCC Clinical Trials Office
[email protected]
843-792-9321
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Dose-limiting toxicity (DLT) incidence12 months

    The proportion of DLT events will be summarized using exact binomial confidence intervals. This proportion will be calculated based on the DLT evaluable analysis set.

  • Binary patient level indicator for manufacturing success12 months

    Defined by TIL generation \>1 x 109 followed by successful TIL infusion.